欧洲机构支持使用莱卡尼马布治疗阿尔茨海默病, European agency backs lecanemab for Alzheimer's, paving way for potential EU approval.

欧洲药物管理局委员会重申对早期阿尔茨海默病药物lecanemab的积极立场,为欧盟,冰岛,列支敦士登和挪威的潜在批准奠定了基础. The European Medicines Agency's committee has reaffirmed its positive stance on lecanemab, a drug for early Alzheimer's disease, setting the stage for potential approval across the EU, Iceland, Liechtenstein, and Norway. 如果获得授权,这些区域将可获得该药物,美国、日本、中国和若干其他国家将加入其目前批准的国家行列。 If authorized, the drug will be available in these regions, joining its current approvals in the US, Japan, China, and several other countries. Lecanemab旨在解决对新的早期阿尔茨海默氏病治疗的迫切需要。 Lecanemab aims to address the significant need for new early-stage Alzheimer's treatments.